Avoro Life Sciences Fund LLC
Raised
$3.5B
Investors
292
Min Invest
$1,000,000
AltStreet Analysis
·Generated from EDGAR primary sources
Avoro Life Sciences Fund LLC is a Delaware pooled investment fund managed by Avoro Capital Advisors LLC. This amended filing reports $3.45 billion raised from 292 investors under Rule 506(b) and 3(c) exemptions, with a $1.0 million minimum investment. Executive officers include Behzad Aghazadeh, Scott Epstein, and Neil Cammarosano.
This is a substantial life sciences-focused pooled investment fund utilizing the 506(b) private placement exemption paired with 3(c) for investment company status. The $1.0 million minimum is consistent with institutional and qualified purchaser funds in the alternative investment space, and the capital raised places it in the upper tier of sector-focused alternative funds.
Data Flags
EDGAR Filing Data
Form D — Primary Source
View on SEC.govFilings on Record
Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.
Fund Family
Every vehicle in this manager's series as it appears on EDGAR, newest generation first. Sold-to-date and investor counts are each vehicle's latest Form D.
Fund family
Avoro Life Sciences Fund2 vehicles · 0 generations · since 2016 · $5.63B sold across the family
| Vehicle | Role | First filed | Status | Sold | Investors |
|---|---|---|---|---|---|
| Unnumbered · first filed 2016-10-11 · 2 vehicles · $5.63B sold · 582 investors | |||||
| Avoro Life Sciences Fund LLCthis issuer | 2016-10-11 | raising | $3.45Bcombined | 292 | |
| Avoro Life Sciences Offshore Fund Ltd. | offshore | 2016-10-11 | raising | $2.18B | 290 |
Grouped from Form D issuer names (generation, sleeve, jurisdiction and legal-form tokens removed); a name-only match, so abbreviated or renamed vehicles can be missed. Sold and investor figures are each vehicle's latest Form D; sleeves that report the same figure share one family-wide total and are counted once. Performance lines are what a public pension plan reports for its own interest in that fund, net, on the plan's cash flows and valuation date; they are not the general partner's figures.
In the Terminal
Filing events
9
latest May 1, 2026
Critical / warning
0 / 1
5 watch · 3 info
Statements extracted
0
none on file
NAV prints
0
none on file
Offering chains
1
raising
Latest event Sold increase · May 1, 2026
SEC.govInvestor
- 9 filing events with values and deltas, latest 2026-05-01, and alerts on the next one
- 1 offering timeline: velocity, share raised, first-sale lag, stalled flags
Pro
- This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
- The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Adviser of Record (Form ADV)
CRD 154091 · SEC-registered adviser · lists this fund on Schedule D 7.B.(1) as a hedge fund
Auditor named on Form ADV: KPMG LLP · PCAOB-registered per the adviser
From the adviser's Form ADV as loaded from the SEC bulk data through December 31, 2024, joined on this issuer's Form D file number. Fund-level figures and the adviser's full fund roster are in the terminal.
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
- Avoro Capital Advisors LLC
Promoter · New York, NY
Behzad Aghazadeh
Executive Officer · New York, NY
Scott Epstein
Executive Officer · New York, NY
Neil Cammarosano
Executive Officer · New York, NY
- Avoro Capital GP, LLC
Promoter · New York, NY
- Avoro Capital L.P.
Promoter · New York, NY
Placement Agents and Sales Compensation (Form D)
Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.
Far Hills Group LLCCRD 000032243 on BrokerCheck
Associated broker-dealer: None · NEW YORK, NY · Soliciting in all states
Questions About Avoro Life Sciences Fund LLC
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is Avoro Life Sciences Fund LLC?
Avoro Life Sciences Fund LLC is a Delaware limited liability company that filed a Form D with the SEC on May 1, 2026 as a hedge fund. The filing claims Rule 506(b), Section 3(c), Section 3(c)(7) for an offering of pooled investment fund interests.
Is Avoro Life Sciences Fund LLC legit?
AltStreet does not rate legitimacy; it reports the public record. Avoro Life Sciences Fund LLC filed a Form D with the SEC on May 1, 2026 claiming Rule 506(b), Section 3(c), Section 3(c)(7). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $3,454,353,055 sold to 292 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is Avoro Life Sciences Fund LLC registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Avoro Life Sciences Fund LLC claimed Rule 506(b), Section 3(c), Section 3(c)(7) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has Avoro Life Sciences Fund LLC raised?
Avoro Life Sciences Fund LLC reported $3,454,353,055 sold from 292 investors in an offering of indefinite size as of the Form D filed May 1, 2026. The filing states that the figure is combined across related vehicles, so it is not this entity's figure alone.
Who can invest in Avoro Life Sciences Fund LLC?
The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. Because the fund also relies on Section 3(c)(7), each investor must be a qualified purchaser, generally an individual with at least $5 million in investments. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $1,000,000.
What is the minimum investment in Avoro Life Sciences Fund LLC?
The Form D lists $1,000,000 as the minimum investment accepted from any outside investor as of May 1, 2026. Issuers can waive their own minimums, and the figure does not include fees.
Who is selling Avoro Life Sciences Fund LLC and how are they paid?
The Form D names Far Hills Group LLC (CRD 000032243), associated with None as the recipient of sales compensation soliciting in all states. Sales commissions are reported as $37,172,277 and finders' fees as $0. Form D allows these to be estimates.
Who is behind Avoro Life Sciences Fund LLC?
The Form D lists 6 related persons: Avoro Capital Advisors LLC, promoter (Managing Member of the Issuer); Behzad Aghazadeh, executive officer (Portfolio Manager and Managing Partner of Avoro Capital Advisors LLC); Scott Epstein, executive officer (Partner, Chief Operating Officer & Chief Compliance Officer of Avoro Capital Advisors LLC); Neil Cammarosano, executive officer (Chief Financial Officer of Avoro Capital Advisors LLC); Avoro Capital GP, LLC, promoter (General Partner of Avoro Capital L.P); Avoro Capital L.P., promoter (Direct owner of Avoro Capital Advisors LLC). Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is Avoro Life Sciences Fund LLC located?
The issuer's address on its SEC filings is 110 Greene Street, Suite 800, New York, NY 10012. Its phone number of record is (212) 937-4975. It is organized under the laws of Delaware.
How long is the Avoro Life Sciences Fund LLC offering open?
The issuer indicated that the offering is intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open; 16 amendments are on record for this CIK.
How large is Avoro Life Sciences Fund LLC?
The issuer declined to disclose its net asset value range on the Form D, which the form permits.
Is this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.